試す - 無料

Omission of phytochemistry in UG Dravyaguna curriculum

Chronicle Pharmabiz

|

November 13, 2025

PHYTOCHEMISTRY has been once an integral part of the undergraduate syllabus by Central Council of Indian Medicine.

- Dr. Amritpal Singh

Recently, Dravyaguna syllabus has been revised by the National Commission of Indian Medicine and surprisingly enough, phytochemistry has been omitted and number of the medicinal plants has been reduced considerably. This is the striking difference between the syllabus designed by CCIM and NCISM.

What is the connection between dravyaguna and phytochemistry? Dravyaguna is closely allied to botany, ethnobotany, pharmacognosy and pharmacology. Dravyaguna was not included in the eight branches coined for Ayurveda but was carved out as a separate subject. Dravyaguna is often categorized as non-clinical subject providing a basis to the clinical subjects.

Some experts are advocating an interdisciplinary nature of dravyaguna and ethnopharmacology. In fact, several articles published in journals related to integrative medicine have addressed ayurvedic medicine as reverse pharmacology and dravyaguna as reverse pharmacognosy. The terms reverse pharmacology or ethnopharmacology serves the same purpose of providing the evidence-based approach to the plant based medicinal systems.

An average BAMS student is least interested in learning dravyaguna skills while pursuing graduation. Probably, lack of pedagogy tools and language barrier can be the possible culprits. However, with the publication and the availability of the quality books, the art of teaching and learning is gradually evolving.

A relevant portion of pharmacology is included in the undergraduate syllabus of dravyaguna. As an observation, it can be argued that the majority of the Ayurveda professionals are inclined towards pharmacology rather than the medicinal herbs.

The Genesis of retaining pharmacology and omitting phytochemistry by NCISM from the latest syllabus is beyond imagination. An integration of dravyaguna with pharmacology and phytochemistry can yield better results for enhancing practical accountability.

Chronicle Pharmabiz からのその他のストーリー

Chronicle Pharmabiz

Chronicle Pharmabiz

Home-grown CAR-T cell therapies gaining ground

INDIAN biotech and pharmaceutical companies are actively working on innovative solutions to make CART cell therapy both accessible and cost-effective.

time to read

4 mins

November 27, 2025

Chronicle Pharmabiz

NPPA extends price fixation on orthopaedic implants for 1 year

IN a move that will disappoint the industry, the National Pharmaceutical Pricing Authority (NPPA) has extended the ceiling price fixation it imposed on orthopaedic knee implants for knee replacement system for one more year.

time to read

1 mins

November 27, 2025

Chronicle Pharmabiz

FICCI envisages it's Smart AAMs to boost healthcare

In line with the Central Government's vision of comprehensive primary healthcare, FICCI Swasth Bharat Task Force has undertaken a transformative initiative titled 'Smart Ayushman Arogya Mandirs-AAMs' (earlier called Health & Wellness Centres) aimed at strengthening the primary healthcare delivery system across India.

time to read

1 min

November 27, 2025

Chronicle Pharmabiz

DoP asked to bring policy for affordable drug pricing

THE Parliamentary Panel on Chemicals and Fertilisers has recommended to the Department of Pharmaceutical (DoP) to take steps to come out with a pharmaceutical policy with thrust to provide both scheduled and nonscheduled formulations at affordable prices.

time to read

1 mins

November 27, 2025

Chronicle Pharmabiz

Ramaiah emphasises need for bone health and osteoporosis diagnosis

RAMAIAH Memorial Hospital (RMH), a multi-superspecialty quaternary care hospitals emphasises on bone health and osteoporosis diagnosis. It calls for timely screening and diagnosis through the new and advanced DXA scanner with superior and accurate test results.

time to read

2 mins

November 27, 2025

Chronicle Pharmabiz

Nathealth calls for action in 2026-27 Union Budget

NATHEALTH has submitted its budget 2026-27 recommendations to the Union government, outlining a roadmap to strengthen healthcare delivery, foster innovation, and expand insurance and preventive coverage.

time to read

1 mins

November 27, 2025

Chronicle Pharmabiz

Hotspots & growth opportunities in biomanufacturing

THE Indian bioeconomy has grown from US$ 10 billion in 2014 to US$ 165.7 billion in 2024, and is likely reach US$ 300 billion by 2030.

time to read

3 mins

November 27, 2025

Chronicle Pharmabiz

Omega Hospitals acquires Cytecare Hospitals

Morgan Stanley PE backed Hyderabad-based Omega Hospitals has acquired Cytecare Hospitals, a leading cancer care hospital in Bengaluru.

time to read

2 mins

November 27, 2025

Chronicle Pharmabiz

Devices sector hails withdrawal of QCOs

THE medical devices manufacturers industry in the country has welcomed the Central government's decision to withdraw multiple Quality Control Orders (QCOs) imposed on essential raw materials across various industries, including the medical devices sector.

time to read

1 min

November 27, 2025

Chronicle Pharmabiz

'There is urgent need for tech-focused regulatory approach for med devices'

THE Indian healthcare industry has evolved at a breakneck pace, but its regulatory framework has struggled to keep up to its speed of development.

time to read

2 mins

November 27, 2025

Listen

Translate

Share

-
+

Change font size